Ayman Abouzayed

419 total citations
28 papers, 307 citations indexed

About

Ayman Abouzayed is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ayman Abouzayed has authored 28 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Radiology, Nuclear Medicine and Imaging, 21 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ayman Abouzayed's work include Radiopharmaceutical Chemistry and Applications (20 papers), Peptidase Inhibition and Analysis (14 papers) and Prostate Cancer Treatment and Research (11 papers). Ayman Abouzayed is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (20 papers), Peptidase Inhibition and Analysis (14 papers) and Prostate Cancer Treatment and Research (11 papers). Ayman Abouzayed collaborates with scholars based in Sweden, Russia and Greece. Ayman Abouzayed's co-authors include Anna Orlova, Vladimir Tolmachev, Sara S. Rinne, Ulrika Rosenström, Bogdan Mitran, Mats Larhed, Zohreh Varasteh, Anzhelika Vorobyeva, John Löfblom and Stefan Ståhl and has published in prestigious journals such as Scientific Reports, International Journal of Molecular Sciences and Journal of Controlled Release.

In The Last Decade

Ayman Abouzayed

27 papers receiving 307 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ayman Abouzayed Sweden 12 226 149 116 59 39 28 307
Michael Meisenheimer Germany 11 202 0.9× 128 0.9× 167 1.4× 57 1.0× 41 1.1× 16 312
В. И. Чернов Russia 11 262 1.2× 194 1.3× 51 0.4× 64 1.1× 28 0.7× 49 375
Jennie Malmberg Sweden 11 398 1.8× 224 1.5× 74 0.6× 136 2.3× 30 0.8× 12 460
Delphine Vimont France 12 149 0.7× 112 0.8× 89 0.8× 70 1.2× 76 1.9× 24 313
Shorouk Dannoon United States 9 165 0.7× 71 0.5× 83 0.7× 61 1.0× 37 0.9× 18 290
Roman Zelchan Russia 8 197 0.9× 111 0.7× 56 0.5× 40 0.7× 21 0.5× 55 264
Luis David Jiménez‐Franco Germany 9 219 1.0× 256 1.7× 121 1.0× 48 0.8× 66 1.7× 13 420
Debra Stuurman Netherlands 11 133 0.6× 144 1.0× 175 1.5× 106 1.8× 54 1.4× 31 364
Stefan Wiessalla Germany 4 399 1.8× 157 1.1× 354 3.1× 39 0.7× 55 1.4× 6 485
Gesche Wieser Germany 7 239 1.1× 101 0.7× 345 3.0× 29 0.5× 41 1.1× 9 448

Countries citing papers authored by Ayman Abouzayed

Since Specialization
Citations

This map shows the geographic impact of Ayman Abouzayed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ayman Abouzayed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ayman Abouzayed more than expected).

Fields of papers citing papers by Ayman Abouzayed

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ayman Abouzayed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ayman Abouzayed. The network helps show where Ayman Abouzayed may publish in the future.

Co-authorship network of co-authors of Ayman Abouzayed

This figure shows the co-authorship network connecting the top 25 collaborators of Ayman Abouzayed. A scholar is included among the top collaborators of Ayman Abouzayed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ayman Abouzayed. Ayman Abouzayed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abouzayed, Ayman, Luke R. Odell, Vladimir Tolmachev, et al.. (2025). Synthesis and preclinical evaluation of gastrin releasing peptide receptor antagonist [18F]MeTz-PEG2-RM26 for positron emission tomography. EJNMMI Radiopharmacy and Chemistry. 10(1). 14–14. 1 indexed citations
2.
Yashaswini, Chittampalli N., Bogdan Mitran, John Löfblom, et al.. (2025). PDGFRß targeted positron emission tomography as a non-invasive biomarker for activated hepatic stellate cells: lasts steps before clinical translation. EJNMMI Radiopharmacy and Chemistry. 10(1). 80–80.
3.
Abouzayed, Ayman, A Mattsson, Vladimir Tolmachev, et al.. (2024). GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics. Pharmaceutics. 16(4). 513–513. 5 indexed citations
4.
Mattsson, A, Ayman Abouzayed, Berthold A. Nock, et al.. (2024). Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology. EJNMMI Radiopharmacy and Chemistry. 9(1). 3 indexed citations
5.
Zhang, Jie, Sara S. Rinne, E. Bjorklund, et al.. (2024). Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts. ACS Pharmacology & Translational Science. 7(10). 3228–3240. 2 indexed citations
6.
7.
Zhang, Jie, Tianqi Xu, Ayman Abouzayed, et al.. (2024). Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.. Journal of Controlled Release. 370. 468–478. 4 indexed citations
8.
9.
10.
Abouzayed, Ayman, Sophia Hober, Roman Zelchan, et al.. (2023). The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity. Diagnostics. 13(9). 1611–1611. 3 indexed citations
11.
Abouzayed, Ayman, et al.. (2023). Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics. Biomolecules. 13(7). 1134–1134. 6 indexed citations
12.
Abouzayed, Ayman, et al.. (2023). 177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry. Frontiers in Oncology. 13. 1221103–1221103. 3 indexed citations
13.
Rinne, Sara S., Ayman Abouzayed, Anzhelika Vorobyeva, et al.. (2022). Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. Biomedicines. 10(6). 1293–1293. 5 indexed citations
14.
Rinne, Sara S., et al.. (2022). Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands. Pharmaceutics. 14(5). 1098–1098. 15 indexed citations
15.
Rinne, Sara S., Ayman Abouzayed, Katherine Gagnon, Vladimir Tolmachev, & Anna Orlova. (2021). 66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga]Ga-NOTA-PEG2-RM26. Scientific Reports. 11(1). 3631–3631. 15 indexed citations
16.
Abouzayed, Ayman, Sara S. Rinne, Jens Sørensen, et al.. (2021). Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer. Pharmaceutics. 13(2). 182–182. 11 indexed citations
17.
18.
Abouzayed, Ayman, Sara S. Rinne, Kristina Westerlund, et al.. (2020). Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer. Pharmaceutics. 12(10). 977–977. 12 indexed citations
19.
Deyev, Sergey M., Anzhelika Vorobyeva, Alexey Schulga, et al.. (2019). Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. International Journal of Biological Macromolecules. 145. 216–225. 24 indexed citations
20.
Rinne, Sara S., Bogdan Mitran, Ayman Abouzayed, et al.. (2019). Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. Scientific Reports. 9(1). 17710–17710. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Meisenheimer Breakdown of academic impact, for papers by В. И. Чернов Breakdown of academic impact, for papers by Jennie Malmberg Breakdown of academic impact, for papers by Delphine Vimont Breakdown of academic impact, for papers by Shorouk Dannoon Breakdown of academic impact, for papers by Roman Zelchan Breakdown of academic impact, for papers by Luis David Jiménez‐Franco Breakdown of academic impact, for papers by Debra Stuurman Breakdown of academic impact, for papers by Stefan Wiessalla Breakdown of academic impact, for papers by Gesche Wieser
Rankless by CCL
2026